Neogene Therapeutics, Inc. is a biomedical company dedicated to developing next-generation T cell therapies that target mutated proteins (neo-antigens) in cancer. Neogene is developing a minimally invasive and scalable platform that will enable targeting of neo-antigens occurring in individual patients with fully personalized and genetically engineered “Designer T cells” that have been optimized to seek and destroy tumor cells based on neo-antigens.
Funding Rounds 1
|14.09.2020||Series A||$110M||-||Neogene Th...|
Mentions in press and media 2